Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination). MedDRA version: 19.1 Level: LLT Classification code 10019982 Term: Herpes zoster NOS System Organ Class: 100000004862
Conditions
Sponsors
GlaxoSmithKline Biologicals
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, ability to have scheduled contacts to allow evaluation during the study). Or subjects with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, availability for follow-up contacts); •Written informed consent obtained from the subject prior to performance of any study specific procedure; •Subject who participated in ZOSTER-006 or ZOSTER-022 studies and received at least one dose of HZ/su vaccine. Additional inclusion criteria for the 1-Additional Dose, Revaccination and Control groups, ONLY: •Female subjects of non-childbearing potential may be enrolled in this study. -Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause. •Female subjects of childbearing potential may be enrolled in this study, if the subject: -has practiced adequate contraception for 30 days prior to vaccination, and -has a negative pregnancy test on the day of vaccination and -has agreed to continue adequate contraception during the entire treatment period and for 2 months after com-pletion of the vaccination series. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1716 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 6865
Exclusion criteria
Exclusion criteria: •Use of any investigational or non-registered product (pharmaceutical product or device) at the time of enrolment or planned use during the study period; •Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than the HZ/su vaccine administered in studies ZOSTER-006/022); •Chronic administration (defined as > 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting six months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study period. For corticosteroids, this will mean prednisone = 20 mg/day or equivalent. A prednisone dose of 14 consecutive days) of oral and/or par-enteral antiviral agents that are active against VZV (acyclovir, valacyclovir, famciclovir, etc. ) and planned to be used during the study period for an indication other than to treat suspected or confirmed HZ or an HZ-related complication (topical use of these antiviral agents is allowed). •Important underlying illness that in the opinion of the investigator would be expected to interfere significantly during the study; Additional exclusion criteria for the 1-Additional Dose, Revaccination and Control groups, ONLY: •Subjects who experienced an SAE from first vaccination in the previous ZOSTER-006/022 studies to enrolment in study ZOSTER-049 that was considered related to study vaccine by either the investigator or the sponsor; •Subjects with a new onset of a pIMD or exacerbation of a pIMD from first vaccination in the previous ZOSTER-006/022 studies to enrolment in study ZOSTER-049; •Use of any investigational or non-registered product (pharmaceutical product or device) within 30 days preceding the first dose of study vaccine or planned use during the study period; •Administration or planned administration of any other immunizations within 30 days before the first study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines (i.e., inactivated and subunit vaccines, including inactivated and subunit influenza vaccines for seasonal or pandemic flu, with or without adjuvant) may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine; •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation (such as materials that may possibly contain latex -gloves, syringes, etc.). Please note, the vaccine and vials in this study do not contain latex;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the Vaccine Efficacy (VE) in the prevention of Herpes Zoster (HZ) over the total duration of the ZOSTER-049 (Z49) study overall as measured by the reduction in HZ risk in subjects =50 years of age at the time of first vaccination in the ZOSTER-006/022 (Z6/22) studies.;Secondary Objective: VE in HZ prevention in subjects of each age*: 1 During Z49 VE in HZ prevention in subjects =50Y & each age*: 2 From 1 month p-Dose2 in Z6/22 to Z49 end 3 Over each Y from 1 month p-Dose2 in Z6/22 VE in PHN prevention in subjects =50Y & each age*: 4 During Z49 5 From 1 month p-Dose2 in Z6/22 to Z49 end Immuno at Y 5, 6, 7, 8, 9 & 10 & beyond Z6/22 p-1’ vacc. in subjects =50Y & in each age*: 6 HI 7 CMI Immuno at Y 5, 6, 7, 8, 9 & 10 & beyond Z6/22 p-1’ vacc. in subjects =50Y with conf. HZ: 8 HI 9 CMI Immuno 1 month p-1st additional HZ/su dose (1AdD** & Rev & Ctrl): 10 HI 11 CMI Immuno 1 month p-2nd additional HZ/su dose (Rev & Ctrl): 12 HI 13 CMI Immuno at Y 1, 2, 3, 4, 5 & 6 of Z49 (1AdD, Rev & Ctrl): 14 HI 15 CMI 16 Safety & reacto (1AdD & Rev) 17 Safety (LTFU & Ctrl) *Ages: 50-59, 60-69, =60 & =70Y at Day 1 in Z6/22. Y=year; p-=post; 1’=primary; HI=Humoral Immuno; CMI=Cell-Mediated Immuno. **Groups: 1AdD=1-Additional Dose; Rev=Revaccination; Ctrl=Control.;Primary end point(s): Confirmed HZ cases (LTFU and Control groups).;Timepoint(s) of evaluation of this end point: During the entire study period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Confirmed HZ cases. 2. PHN cases. 3. Antigen-gE humoral immunogenicity (Anti-gE Ab concentrations as determined by ELISA). 4. CMI in terms of frequencies of antigen-specific CD4+ T cells (Frequencies of CD4+ T cells with antigen-specific Interferon gamma (IFN-?) and/or Interleukin-2 (IL-2) and/or Tumour Ne-crosis Factor alpha (TNF-a) and/or CD40 Ligand (CD40L) secretion/expression to gE as determined by ICS). 5. Solicited local and general symptoms in subjects administered with 1 or 2 additional doses of HZ/su vaccine (1-Additional Dose and Revaccination groups). 6. Unsolicited AEs in subjects administered with 1 or 2 additional doses of HZ/su vaccine (1-Additional Dose and Revaccination groups). 7. Occurrence and relationship to vaccination of all SAEs (1-Additional Dose, Revaccination and Control groups). 8. Occurrence of SAEs related to investigational vaccine, related to study participation or to GSK concomitant medication/vaccine (All subjects). 9. Occurrence and relationship to vaccination of all AEs of specific interest: Potential immune-mediated diseases (pIMDs) (1-Additional Dose, Revaccination and Control groups).;Timepoint(s) of evaluation of this end point: 1 and 2. 1 month post dose 2 in the previous Z-006/022 studies to study end. 3 and 4. At months 0, 12, 24, 36, 48, 60 and 72 (LTFU HI and CMI subsets, 1-Additional Dose, Revaccination and Control groups), and at Month 1 (1-Additional Dose, Revaccination and Control groups), and at Month 3 (Revaccination and Control groups). 5. 7 days (Days 0-6) after each vaccination. 6. 30 days (Days 0-29) after each vaccination. 7 and 9. From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month 0 until 12 months after last HZ/su vaccination (Revaccination group). 8. During the entire study. | — |
Countries
Australia, Brazil, Canada, Czech Republic, Estonia, Finland, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, Spain, Sweden, Taiwan, United Kingdom, United States
Contacts
Public ContactClinical Disclosure Advisor
GlaxoSmithKline Bioloigicals
Outcome results
None listed